OP-1250
OP-1250-001
Phase 2 small_molecule completed
Quick answer
OP-1250 for Hormone Receptor Positive Breast Carcinoma is a Phase 2 program (small_molecule) at Olema Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Olema Pharmaceuticals
- Indication
- Hormone Receptor Positive Breast Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed